2023
Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement
Iskander M, Jamil Y, Forrest J, Madhavan M, Makkar R, Leon M, Lansky A, Ahmad Y. Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement. Structural Heart 2023, 7: 100169. PMID: 37520138, PMCID: PMC10382985, DOI: 10.1016/j.shj.2023.100169.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementCerebral embolic protection devicesCerebral embolic protectionAortic valve replacementEmbolic protection devicesValve replacementEmbolic protectionSymptomatic severe aortic stenosisSevere aortic stenosisLow-risk patientsPredictors of strokeOccurrence of complicationsRisk of strokeRecent trial dataRelevant clinical studiesOverall evidence baseExpansion of TAVRFeared complicationAortic stenosisSurgical riskTreatment optionsWorse outcomesClinical studiesPatientsTrial data
2021
Meta-Analysis of Usefulness of Cerebral Embolic Protection During Transcatheter Aortic Valve Implantation
Ahmad Y, Howard JP. Meta-Analysis of Usefulness of Cerebral Embolic Protection During Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2021, 146: 69-73. PMID: 33556360, PMCID: PMC8082278, DOI: 10.1016/j.amjcard.2021.01.023.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationCerebral embolic protectionRisk of strokeAortic valve implantationEmbolic protectionValve implantationClinical outcomesNon-disabling strokePrimary end pointNew ischemic lesionsRandomized clinical trialsTotal lesion volumeSignificant differencesFeared complicationIschemic lesionsClinical trialsLesion volumeStroke rateNeuroimaging outcomesMeta-AnalysisSystematic reviewTrial dataStrokeEnd pointSignificant heterogeneitySingle Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Clinical Trials
Ahmad Y, Howard JP, Madhavan MV, Leon MB, Makkar RR. Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Clinical Trials. Cardiovascular Revascularization Medicine 2021, 34: 46-53. PMID: 33514490, PMCID: PMC8814464, DOI: 10.1016/j.carrev.2021.01.016.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementDual antiplatelet therapyAortic valve replacementLife-threatening bleedingRisk of strokeMyocardial infarctionMajor bleedingCardiac deathAntiplatelet therapyValve replacementRandomized clinical trialsSignificant differencesIschemic endpointsPrimary endpointSecondary endpointsTotal patientsClinical trialsBleedingMeta-AnalysisTrialsStrokeEndpointDeathInfarctionPatients
2020
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials
Ahmad Y, Howard JP, Arnold AD, Cook CM, Prasad M, Ali ZA, Parikh MA, Kosmidou I, Francis DP, Moses JW, Leon MB, Kirtane AJ, Stone GW, Karmpaliotis D. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. European Heart Journal 2020, 41: 3228-3235. PMID: 32118272, PMCID: PMC7557472, DOI: 10.1093/eurheartj/ehaa135.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryPercutaneous coronary interventionDrug-eluting stentsMain coronary artery diseaseCoronary artery diseaseMyocardial infarctionCardiac deathUnplanned revascularizationCause mortalityCoronary interventionArtery diseaseLeft main coronary artery diseaseRandomized clinical trial evidenceSimilar long-term mortalityArtery bypass graft surgerySignificant differencesUnplanned revascularization proceduresWeighted mean followBypass graft surgeryCoronary artery bypassPrimary efficacy endpointClinical trial evidenceLong-term mortalityRisk of strokeGold standard therapy
2013
Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke risk